复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02696 复宏汉霖

已收盘 05-15 16:09:05

67.500

+0.150

+0.22%

最高68.500	最低66.000	成交量72.63万
今开67.000	昨收67.350	日振幅3.71%
总市值366.53亿	流通市值233.60亿	总股本5.43亿
成交额4,841万	换手率0.21%	流通股本3.46亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02696","market":"HK","secType":"STK","nameCN":"复宏汉霖","latestPrice":67.5,"timestamp":1778832545008,"preClose":67.35,"halted":0,"volume":726309,"delay":0,"changeRate":0.0022271714922049842,"floatShares":346074397,"shares":543000000,"eps":1.509618,"marketStatus":"已收盘","change":0.15,"latestTime":"05-15 16:09:05","open":67,"high":68.5,"low":66,"amount":48414192,"amplitude":0.03712,"askPrice":67.6,"askSize":300,"bidPrice":67.5,"bidSize":300,"shortable":3,"etf":0,"ttmEps":1.680343,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779067800000},"marketStatusCode":5,"adr":0,"listingDate":1569340800000,"exchange":"SEHK","adjPreClose":67.35,"openAndCloseTimeList":[[1778808600000,1778817600000],[1778821200000,1778832000000]],"volumeRatio":0.875559,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02696/tweets","defaultTab":"tweets","newsList":[{"id":"2635908882","title":"复星医药：目前控股子公司复宏汉霖已收到与Eisai合作项下的首付现金款","url":"https://stock-news.laohu8.com/highlight/detail?id=2635908882","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635908882?lang=zh_cn&edition=full","pubTime":"2026-05-15 17:47","pubTimestamp":1778838457,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：董秘您好，请问：复宏汉霖2026年2月授权卫材的7500万美元首付款，在复星医药2026年一季度合并报表中，是否已确认为当期收入？谢谢。复星医药（600196.SH）5月15日在投资者互动平台表示，截至目前，控股子公司复宏汉霖已收到与Eisai合作项下的首付现金款，并根据会计准则进行会计处理。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605153739043716.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605153739043716.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HK0000306685.HKD","BK0188","HK0000306701.USD","HK0000320264.USD","BK0096","HK0000320223.HKD","02696","BK0183","BK0239","HK0000165453.HKD","BK0187","BK0175","BK1161","BK1191","600196","BK0012","BK1593","BK1515","BK0196","BK0028","02196","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635200887","title":"复宏汉霖： HLX48获澳洲临床备案 填补同类药物市场空白","url":"https://stock-news.laohu8.com/highlight/detail?id=2635200887","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635200887?lang=zh_cn&edition=full","pubTime":"2026-05-13 17:38","pubTimestamp":1778665080,"startTime":"0","endTime":"0","summary":"5月13日，复宏汉霖（02696）发布公告，公司自主研发的注射用HLX48（靶向EGFR和c-MET的抗体偶联药物）用于晚期/转移性实体瘤治疗的1期临床试验已获得相关人类研究伦理委员会的批准，并通过澳大利亚药品管理局的临床试验备案。HLX48是一款靶向c-MET和EGFR的双特异性抗体偶联药物，旨在通过诱导受体介导的内吞作用来实现肿瘤细胞的靶向治疗，并具备良好的安全性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605133736002952.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HK0000306685.HKD","02696","HK0000165453.HKD","HK0000320264.USD","HK0000320223.HKD","BK1161","HK0000306701.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635202592","title":"复宏汉霖(02696)：HLX97在晚期/转移性实体瘤患者中的1期临床研究于中国境内完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2635202592","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635202592?lang=zh_cn&edition=full","pubTime":"2026-05-13 17:03","pubTimestamp":1778663020,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，本公司自主研发的HLX97 在晚期/转移性实体瘤患者中的1期临床研究于中国境内完成首例患者给药。Part 2在HR 阳性HER2阴性局部晚期或转移性乳腺癌患者中开展，其中两个组是不同剂量的HLX97联合氟维司群的联合治疗组，一个组为氟维司群单药治疗组。2026 年3月，HLX97在晚期/转移性实体瘤患者中的1期临床试验申请获国家药品监督管理局批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441210.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"复宏汉霖(02696)：HLX97在晚期/转移性实体瘤患者中的1期临床研究于中国境内完成首例患者给药","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000320264.USD","HK0000306685.HKD","HK0000165453.HKD","02696","BK1161","HK0000320223.HKD","HK0000306701.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634557442","title":"复宏汉霖(02696)：西妥昔单抗注射液生物类似药HLX05-N用于转移性结直肠癌(mCRC)治疗的 1期临床试验申请获美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2634557442","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634557442?lang=zh_cn&edition=full","pubTime":"2026-05-10 18:31","pubTimestamp":1778409109,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，本公司自主研发的西妥昔单抗注射液生物类似药HLX05-N用于转移性结直肠癌治疗的1期临床试验申请获美国药品监督管理局批准。本公司拟于条件具备后于美国开展相关1期临床试验。西妥昔单抗能与正常和肿瘤细胞中的EGFR特异性结合，竞争性抑制EGF等配体的结合。此外，西妥昔单抗还可通过抗体依赖的细胞毒性对部分肿瘤发挥抗肿瘤作用。经药学和非临床比对研究证明，HLX05-N与原研西妥昔单抗注射液相似。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439907.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000320223.HKD","BK4585","HK0000306701.USD","BK4588","HK0000320264.USD","02696","HK0000306685.HKD","HK0000165453.HKD","LABU","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634423354","title":"复宏汉霖(02696)：欧盟委员会(EC)批准斯鲁利单抗注射液两项新增适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2634423354","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634423354?lang=zh_cn&edition=full","pubTime":"2026-05-10 18:20","pubTimestamp":1778408419,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，欧盟委员会已批准本公司自主开发的斯鲁利单抗注射液两项新增适应症。此次获批意味着斯鲁利单抗两项新增适应症在所有欧盟成员国及冰岛、列支敦士登和挪威获得批准。此次EC批准主要是基于两项随机、双盲、多中心3期临床研究。此外，2026年3月，斯鲁利单抗获欧洲药品管理局人用药品委员会积极审评意见，推荐批准本次两项新增适应症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439905.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02696","EC","HK0000320264.USD","HK0000306685.HKD","BK1161","HK0000306701.USD","BK4201","HK0000165453.HKD","HK0000320223.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144584436","title":"复宏汉霖更新4月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1144584436","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144584436?lang=zh_cn&edition=full","pubTime":"2026-05-07 16:53","pubTimestamp":1778144012,"startTime":"0","endTime":"0","summary":"上海复宏汉霖生物技术股份有限公司于2026年5月7日发布截至2026年4月30日的股份变动月报表。公告显示，公司本月末法定注册股本总额为人民币543,494,853元，较上月保持不变。具体来看，H股已发行股份及非上市股份的数量分别为346,074,397股和197,420,456股，月内无新增发行、回购或注销活动。本月月底，共有7,722,000份股份期权处于获授未失效状态。截至月末，7,742,000份受限制股份单位已授出且未失效，但并未导致公司当月实质新增发行股份或库藏股变动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162320541","title":"复宏汉霖获准在日启动HLX43治疗晚期鳞状非小细胞肺癌的II/III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1162320541","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162320541?lang=zh_cn&edition=full","pubTime":"2026-05-04 17:06","pubTimestamp":1777885593,"startTime":"0","endTime":"0","summary":"上海复宏汉霖生物技术股份有限公司近日宣布，其研发的创新药HLX43已获得日本监管机构批准，将正式启动针对晚期鳞状非小细胞肺癌的II/III期临床试验。该试验旨在评估HLX43在晚期鳞状非小细胞肺癌患者中的疗效与安全性，标志着复宏汉霖在肿瘤免疫治疗领域的全球化布局取得重要进展。随着试验的逐步开展，HLX43的临床数据将为后续注册申报奠定基础，助力公司拓展海外市场。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696","HK0000320223.HKD","HK0000320264.USD","HK0000306701.USD","HK0000306685.HKD","HK0000165453.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632931566","title":"复宏汉霖(02696)：注射用HLX43单药或联合PIMURUTAMAB HLX07于日本获许可开展用于晚期鳞状非小细胞肺癌治疗的国际多中心2/3期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2632931566","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632931566?lang=zh_cn&edition=full","pubTime":"2026-05-04 17:02","pubTimestamp":1777885322,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖(02696)发布公告，近日，向日本药品医疗器械综合机构(PMDA)提交的注射用HLX43(靶向PD-L1抗体偶联药物)(“HLX43”)单药或联合pimurutamab HLX07(重组抗EGFR人源化单克隆抗体注射液)(“HLX07”)对比多西他赛用于晚期鳞状非小细胞肺癌(NSCLC)治疗的国际多中心2/3期临床试验通知获得默示许可。根据有关规定，相关临床试验可以在日本开展。公司拟于条件具备后在日本开展相关临床研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437852.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"复宏汉霖(02696)：注射用HLX43单药或联合PIMURUTAMAB HLX07于日本获许可开展用于晚期鳞状非小细胞肺癌治疗的国际多中心2/3期临床试验","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000320223.HKD","BK1161","02696","HK0000306685.HKD","HK0000306701.USD","HK0000165453.HKD","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198057523","title":"欧盟委员会批准复宏汉霖与Organon的Poherdy®（帕妥珠单抗） 成为欧洲首个获准的Perjeta（帕妥珠单抗）生物类似药","url":"https://stock-news.laohu8.com/highlight/detail?id=1198057523","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198057523?lang=zh_cn&edition=full","pubTime":"2026-04-29 17:31","pubTimestamp":1777455074,"startTime":"0","endTime":"0","summary":"欧盟委员会正式批准了复宏汉霖与Organon公司联合开发的Poherdy®（帕妥珠单抗），该药物成为欧洲地区首个获得上市许可的Perjeta（帕妥珠单抗）生物类似药。这一批准标志着两家公司在生物制药领域取得重要突破，将为欧洲市场提供更多治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","HK0000320264.USD","LU2065170008.USD","BK4585","HK0000306701.USD","HK0000306685.HKD","LU2065169927.USD","BK4588","LU2065171311.SGD","HK0000165453.HKD","OGN","02696","LU2065171402.SGD","BK1161","HK0000320223.HKD","BK4559"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630309173","title":"复宏汉霖(02696)自主研发的POHERDY®于欧盟获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2630309173","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630309173?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:50","pubTimestamp":1777377048,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，公司自主研发的POHERDY 420mg/14mL注射液的上市许可申请 已获欧盟委员会批准，该商品名由N.V. Organon于欧盟注册商标。此次获批意味着POHERDY 在所有欧盟成员国及冰岛、列支敦士登和挪威获得集中上市许可。继于美国获批上市之后，此次POHERDY于欧盟获批上市，是集团产品在国际主流市场获得的又一认可，将进一步推进公司国际化布局的进程，提升公司产品的国际影响力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435508.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02696","HK0000165453.HKD","HK0000306685.HKD","FSXEmain","BK1161","HK0000320223.HKD","FESXmain","HK0000306701.USD","IPOS","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128740396","title":"复宏汉霖旗下汉曲优®获欧盟批准用于治疗HER2阳性早期及转移性乳腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1128740396","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128740396?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:49","pubTimestamp":1777376981,"startTime":"0","endTime":"0","summary":"上海复宏汉霖生物技术股份有限公司近日宣布，其核心产品汉曲优®（通用名：曲妥珠单抗）已获得欧盟委员会批准，用于治疗HER2阳性早期乳腺癌及转移性乳腺癌。此项批准标志着公司创新研发成果获得国际主流市场认可，为欧洲患者提供了重要的治疗选择。\nHER2阳性乳腺癌是一种侵袭性较强的乳腺癌亚型，汉曲优®作为曲妥珠单抗的生物类似药，在疗效与安全性方面与原研药高度相似。此次获批将进一步提升复宏汉霖在全球生物药市场的竞争力，并为其国际化战略注入新动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000306701.USD","02696","BK1161","HK0000165453.HKD","HK0000320264.USD","HK0000320223.HKD","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189910896","title":"复宏汉霖Hlx07联合汉斯状®治疗晚期鳞状非小细胞肺癌II/III期临床试验获准在澳大利亚启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1189910896","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189910896?lang=zh_cn&edition=full","pubTime":"2026-04-24 18:16","pubTimestamp":1777025795,"startTime":"0","endTime":"0","summary":"上海复宏汉霖生物技术股份有限公司宣布，其创新药Hlx07联合汉斯状®（HLX10）用于治疗晚期鳞状非小细胞肺癌的II/III期临床试验，已获得澳大利亚监管机构批准正式启动。\n该临床试验旨在评估Hlx07这一靶向EGFR的人源化单克隆抗体，与公司自主研发的PD-1抑制剂汉斯状®联合疗法的有效性与安全性。研究将聚焦于晚期鳞状非小细胞肺癌患者群体，这是肺癌中一种常见的亚型。\n此次在澳大利亚获批开展临床试验，标志着复宏汉霖的这款联合疗法研发项目取得了重要进展，为其全球临床开发布局再添关键一环。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000306685.HKD","02696","HK0000165453.HKD","HK0000320264.USD","HK0000320223.HKD","BK1161","HK0000306701.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629817454","title":"复宏汉霖(02696)：PIMURUTAMAB HLX07联合汉斯状®和化疗对比安慰剂联合汉斯状® 或帕博利珠单抗和化疗一线治疗晚期鳞状 非小细胞肺癌的2/3期临床试验于澳大利亚获批开展","url":"https://stock-news.laohu8.com/highlight/detail?id=2629817454","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629817454?lang=zh_cn&edition=full","pubTime":"2026-04-24 18:15","pubTimestamp":1777025731,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，本公司自主研发的pimurutamab HLX07联合汉斯状(汉斯状)和化疗对比安慰剂联合汉斯状或帕博利珠单抗和化疗一线治疗晚期鳞状非小细胞肺癌的2/3期临床试验已获得相关人类研究伦理委员会的批准，并通过澳大利亚药品管理局的临床试验备案。2026年3月，HLX07联合汉斯状和化疗治疗晚期鳞状非小细胞肺癌的临床试验申请获国家药品监督管理局批准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433500.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"复宏汉霖(02696)：PIMURUTAMAB HLX07联合汉斯状®和化疗对比安慰剂联合汉斯状® 或帕博利珠单抗和化疗一线治疗晚期鳞状 非小细胞肺癌的2/3期临床试验于澳大利亚获批开展","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306685.HKD","HK0000320223.HKD","BK1161","HK0000306701.USD","HK0000165453.HKD","HK0000320264.USD","02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198094205","title":"复宏汉霖授予董事股份购回授权，规模达已发行股本一成","url":"https://stock-news.laohu8.com/highlight/detail?id=1198094205","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198094205?lang=zh_cn&edition=full","pubTime":"2026-04-24 17:48","pubTimestamp":1777024097,"startTime":"0","endTime":"0","summary":"复宏汉霖(02696)日前公告，拟向董事会授予一般性授权，以回购不超过股东大会通过决议当日已发行H股总数10%的股份。公司在香港联交所主板上市，回购计划将以合法资金来源进行，并根据上市规则和中国相关法律条款完成。\n公告显示，股东大会将于2026年5月19日召开，相关决议如获通过，公司有权在适用条例允许的期间内，于公开市场回购部分已发行H股。董事会认为，该购回有助于维护公司价值与股东利益，相关股份可在回购后根据实际情况进行注销或持作库存股。公司同期提示，2026年5月14日至5月19日将暂停办理过户登记，并以此期间登记在册的股东身份为准。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"复宏汉霖授予董事股份购回授权，规模达已发行股本一成","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158186060","title":"复宏汉霖2025年营收增长16.5%至66.67亿元，聚焦创新研发与全球化布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1158186060","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158186060?lang=zh_cn&edition=full","pubTime":"2026-04-24 17:42","pubTimestamp":1777023751,"startTime":"0","endTime":"0","summary":"复宏汉霖在截至2025年12月31日止年度实现收入人民币66.67亿元，同比上升16.5%，主要来自单抗药物销售及研究与授权服务的持续增长。期内毛利为49.85亿元，增幅达19.1%，带动年内利润达到8.27亿元，较上一年度的8.20亿元小幅增长0.8%。报告期内，研发支出达15.15亿元，同比攀升46.4%，公司持续加码肿瘤免疫治疗等创新药的临床试验与全球商用化推进。财务结构上，截至报告期末，公司资产净值为396.05亿元，同比增长31.4%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"复宏汉霖2025年营收增长16.5%至66.67亿元，聚焦创新研发与全球化布局","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629892567","title":"港股异动 | 复宏汉霖(02696)午后涨近5% 复宏汉霖TCE平台数据首秀2026 AACR","url":"https://stock-news.laohu8.com/highlight/detail?id=2629892567","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629892567?lang=zh_cn&edition=full","pubTime":"2026-04-24 13:42","pubTimestamp":1777009339,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖午后涨近5%，截至发稿，涨3.91%，报82.35港元，成交额6172.94万港元。消息面上，复宏汉霖近日在2026年美国癌症研究协会年会上以壁报形式首次公布了其在研新型CD3×CD28×STEAP1靶向三特异性T细胞衔接器HLX3902的临床前研究数据。西部证券此前发布研报称，预计2026-2028年公司营收为73.97/80.39/95.35亿元，同比增长11.0%/8.7%/18.6%。公司创新布局成效显著，临床数据读出、潜在BD预期等催化较多，叠加生物类似药出海增厚业绩，维持“买入”评级。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433248.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306701.USD","02696","BK1161","HK0000165453.HKD","HK0000320264.USD","BK4585","VXUS","BK4588","HK0000320223.HKD","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628209346","title":"复宏汉霖(02696)授出合共81万份购股权及81万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2628209346","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628209346?lang=zh_cn&edition=full","pubTime":"2026-04-17 20:43","pubTimestamp":1776429784,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖(02696)发布公告，于2026年4月17日，董事会决议根据购股权计划及受限制股份单位计划分别向142名参与者授出合共81万份购股权及81万份受限制股份单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430183.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","HK0000306701.USD","BK1161","02696","HK0000320264.USD","HK0000306685.HKD","HK0000320223.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627419200","title":"复宏汉霖(02696)：西妥昔单抗注射液生物类似药HLX05-N用于转移性结直肠癌(mCRC)治疗的1期临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2627419200","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627419200?lang=zh_cn&edition=full","pubTime":"2026-04-14 17:03","pubTimestamp":1776157393,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，本公司自主研发的西妥昔单抗注射液生物类似药HLX05-N用于转移性结直肠癌治疗的1期临床试验申请获国家药品监督管理局批准。西妥昔单抗能与正常和肿瘤细胞中的EGFR特异性结合，竞争性抑制EGF等配体的结合。此外，西妥昔单抗还可通过抗体依赖的细胞毒性对部分肿瘤发挥抗肿瘤作用。根据IQVIA MIDASTM的资料，2025年度，西妥昔单抗注射液的全球销售额约为16.58亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428303.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"复宏汉霖(02696)：西妥昔单抗注射液生物类似药HLX05-N用于转移性结直肠癌(mCRC)治疗的1期临床试验申请获国家药监局批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","BK1161","HK0000306701.USD","HK0000320223.HKD","HK0000320264.USD","02696","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626416974","title":"港股复宏汉霖涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2626416974","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626416974?lang=zh_cn&edition=full","pubTime":"2026-04-10 14:11","pubTimestamp":1775801495,"startTime":"0","endTime":"0","summary":"每经AI快讯，4月10日，复宏汉霖(02696.HK)涨超4%，截至发稿涨4.44%，报83.55港元，成交额8776.22万港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604103700990064.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604103700990064.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02696","HK0000165453.HKD","HK0000306685.HKD","BK1161","VXUS","HK0000320223.HKD","BK4588","HK0000306701.USD","BK4585","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626169444","title":"港股异动 | 复宏汉霖(02696)涨超4% 汉利康®新增两项适应症获批 7款创新管线将亮相AACR大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2626169444","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626169444?lang=zh_cn&edition=full","pubTime":"2026-04-10 14:01","pubTimestamp":1775800905,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖涨超4%，截至发稿，涨4.44%，报83.55港元，成交额8776.22万港元。消息面上，4月9日，复宏汉霖宣布，公司自主开发和生产的汉利康用于非霍奇金淋巴瘤下的两项新增适应症的补充申请获国家药品监督管理局批准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426980.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","BK4588","HK0000306685.HKD","BK4585","BK1161","HK0000320264.USD","HK0000306701.USD","HK0000320223.HKD","VXUS","02696"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.1382},{"period":"1month","weight":-0.1821},{"period":"3month","weight":-0.0426},{"period":"6month","weight":0.0037},{"period":"1year","weight":0.777},{"period":"ytd","weight":0.1805}],"compareEarnings":[{"period":"1week","weight":-0.0089},{"period":"1month","weight":0.02},{"period":"3month","weight":-0.0067},{"period":"6month","weight":-0.0253},{"period":"1year","weight":0.1163},{"period":"ytd","weight":0.0296}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复宏汉霖生物技术股份有限公司是一家主要从事生物制药研发、生物制药服务及生物制药生产与销售的中国公司。该公司的主要产品包括汉曲优（注射用曲妥珠单抗）、汉奈佳（马来酸奈拉替尼片）、汉斯状（斯鲁利单抗注射液）、汉利康（利妥昔单抗注射液）、汉达远（阿达木单抗注射液）、汉贝泰（贝伐珠单抗注射液）等。该公司的产品主要应用于乳腺癌辅助治疗、转移性乳腺癌及转移性胃癌治疗、转移性非鳞状非小细胞肺癌、多关节型幼年特发性关节炎治疗等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.044394},{"month":2,"riseRate":0.714286,"avgChangeRate":0.117695},{"month":3,"riseRate":0.571429,"avgChangeRate":-0.008815},{"month":4,"riseRate":0.857143,"avgChangeRate":0.12138},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.035898},{"month":6,"riseRate":0.666667,"avgChangeRate":0.109389},{"month":7,"riseRate":0.5,"avgChangeRate":0.069459},{"month":8,"riseRate":0.5,"avgChangeRate":-0.024213},{"month":9,"riseRate":0,"avgChangeRate":-0.127435},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.025526},{"month":11,"riseRate":0.571429,"avgChangeRate":0.058675},{"month":12,"riseRate":0.714286,"avgChangeRate":-0.023816}],"exchange":"SEHK","name":"复宏汉霖","nameEN":"HENLIUS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复宏汉霖,02696,复宏汉霖股票,复宏汉霖股票老虎,复宏汉霖股票老虎国际,复宏汉霖行情,复宏汉霖股票行情,复宏汉霖股价,复宏汉霖股市,复宏汉霖股票价格,复宏汉霖股票交易,复宏汉霖股票购买,复宏汉霖股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}